GlaxoSmithKline plc (GSK) Given Average Recommendation of “Hold” by Analysts

Shares of GlaxoSmithKline plc (NYSE:GSK) have received an average rating of “Hold” from the seventeen analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $39.50.

A number of research analysts recently commented on GSK shares. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a report on Tuesday, January 2nd. UBS raised GlaxoSmithKline from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $35.04 to $35.85 in a report on Monday, November 27th. Barclays raised GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 16th. Argus lowered their price target on GlaxoSmithKline to $40.00 and set a “buy” rating on the stock in a report on Thursday, November 30th. Finally, Cowen set a $38.00 price target on GlaxoSmithKline and gave the stock a “hold” rating in a report on Monday, December 11th.

How to Become a New Pot Stock Millionaire

GSK stock traded down $0.38 during midday trading on Wednesday, reaching $37.04. The company had a trading volume of 1,583,259 shares, compared to its average volume of 4,112,126. The company has a current ratio of 0.60, a quick ratio of 0.39 and a debt-to-equity ratio of 4.09. GlaxoSmithKline has a one year low of $34.52 and a one year high of $44.53. The stock has a market cap of $92,780.42, a PE ratio of 46.89, a PEG ratio of 2.08 and a beta of 0.95.

GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 EPS for the quarter, topping the Zacks’ consensus estimate of $0.69 by $0.03. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. The company had revenue of $10.14 billion for the quarter, compared to analysts’ expectations of $9.89 billion. sell-side analysts predict that GlaxoSmithKline will post 2.94 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 12th. Shareholders of record on Friday, February 23rd will be paid a $0.633 dividend. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.50. The ex-dividend date is Thursday, February 22nd. This represents a $2.53 dividend on an annualized basis and a yield of 6.84%. GlaxoSmithKline’s payout ratio is presently 320.26%.

A number of large investors have recently added to or reduced their stakes in the business. Cambridge Investment Research Advisors Inc. increased its stake in GlaxoSmithKline by 5.5% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 107,873 shares of the pharmaceutical company’s stock worth $3,826,000 after acquiring an additional 5,582 shares during the last quarter. OLD Republic International Corp increased its stake in GlaxoSmithKline by 22.1% in the 4th quarter. OLD Republic International Corp now owns 1,538,500 shares of the pharmaceutical company’s stock worth $54,571,000 after acquiring an additional 278,000 shares during the last quarter. Letko Brosseau & Associates Inc. increased its position in shares of GlaxoSmithKline by 3.0% during the 4th quarter. Letko Brosseau & Associates Inc. now owns 1,027,688 shares of the pharmaceutical company’s stock valued at $36,452,000 after purchasing an additional 30,000 shares during the last quarter. Delek Group Ltd. bought a new position in shares of GlaxoSmithKline during the 4th quarter valued at approximately $1,229,000. Finally, Sawtooth Solutions LLC increased its position in shares of GlaxoSmithKline by 316.0% during the 4th quarter. Sawtooth Solutions LLC now owns 24,054 shares of the pharmaceutical company’s stock valued at $853,000 after purchasing an additional 18,272 shares during the last quarter. 10.96% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3302596/glaxosmithkline-plc-gsk-given-average-recommendation-of-hold-by-analysts.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Jewett-Cameron Trading Co  Stake Held by Fort Nelson Partners, LP
Jewett-Cameron Trading Co Stake Held by Fort Nelson Partners, LP
Greenhill & Co.  and GAMCO Investors  Critical Review
Greenhill & Co. and GAMCO Investors Critical Review
STRAKS Tops 1-Day Volume of $24,012.00
STRAKS Tops 1-Day Volume of $24,012.00
KlondikeCoin  Achieves Market Capitalization of $0.00
KlondikeCoin Achieves Market Capitalization of $0.00
Roku  and Its Competitors Head to Head Survey
Roku and Its Competitors Head to Head Survey
Pentair  vs. Metso  Financial Analysis
Pentair vs. Metso Financial Analysis


© 2006-2018 Ticker Report. Google+.